PAMI and the Ministry of Health agreed to reduce costs of oncological medications and special treatments

PAMI and the Ministry of Health agreed to reduce costs of oncological medications and special treatments

October 8, 2024 – 20:52

According to PAMI, this measure will allow savings of an average of 50% in the purchase of medicines.

Pixabay

He Ministry of Health reached an agreement with PAMI to offer discounts on purchase of oncological medications and special treatmentsnot only for its members of the social work for retirees and pensioners, but also for all people in vulnerable situations who need it.

According to PAMI, this measure will allow the saving of a average of 50% on medication purchases.

The Minister of Health, Mario Lugones and the Executive Director of the INSSJP, Esteban Leguizamon They led the signing of the agreement. Also present were the secretary of Administrative Management of the ministry, Cecilia Loccisanothe deputy executive director of the Institute, Carlos Zamparolo and other authorities of the organizations.

In this way, high-cost medications will no longer be administered by the Directorate of Direct Assistance for Special Situations (DADSE)which operates under the orbit of the Ministry of Health. This organization aims to ffacilitate access to treatment for terminal illnesses or serious pathologies in people in vulnerable situations who They do not have any type of health or social work coverageand that they cannot access their medications through provincial ministries, municipal health secretariats or through specific Ministry programs.

From this agreement, PAMI will be the strategic actor in the provision of high priced medicinesnot only for its members but also for all people in vulnerable situations who need it.

The Ministry of Health made progress in reducing the costs of hemophilia medications

On the other hand, the Minister of Health, Mario Lugonesmet today with representatives of the Bayer and Takeda laboratorieswinning companies of the open tender promoted by the Superintendency of Health Services for the joint purchase of the Factor VIII componentessential for the treatment of hemophilia type A.

As highlighted by Health, the joint purchase will allow you to obtain more competitive pricesto the reduce costs by 90 percent from market value. This represents a total of 3,200 million pesos monthlyand an annual savings that exceeds 38.4 billion for the 93 social works that reported cases of this treatment to the Hemophilia Commission of the Superintendence of Health Services.

In this way, patients who need it will be assured of continuous supply of the medication. Thanks to the direct logistics provided by the successful bidder companies, faster and more effective distribution will be achieved.

Source: Ambito

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest Posts

What is the third for?

What is the third for?

The messaging app is planning to update several of its core features. Find out when it will be available to users. WhatsApp, the popular messaging